Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) announced the publication of its Phase 2a clinical trial results in the journal Nature Medicine, demonstrating that a single 21.5 mg dose of SPL026 achieved statistically significant and clinically meaningful reductions in depressive symptoms compared to placebo in patients with moderate-to-severe major depressive disorder. The study met its primary endpoint at two weeks, with a mean difference of -7.35 on the Montgomery-Åsberg Depression Rating Scale (MADRS) (p=0.023), and effects were observed as early as one week post-dose. The treatment was generally well tolerated, with no treatment-related serious adverse events reported.
The findings are significant as they provide robust evidence for the potential of serotonergic agonists in treating major depressive disorder, a condition affecting millions worldwide. The durability of the response was noteworthy: benefits were sustained for up to three months in the open-label phase, and some participants maintained response for up to six months. This supports continued development of Helus Pharma's proprietary serotonergic agonist program, including HLP004 for generalized anxiety disorder. The company's approach focuses on synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity, offering a novel mechanism distinct from conventional antidepressants.
Helus Pharma, the commercial operating name of Cybin Inc., is a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs) for mental health conditions. The company has a robust pipeline, with HLP003 in Phase 3 clinical development for major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. HLP004 is in Phase 2 for generalized anxiety disorder, and additional investigational NSAs are in the research portfolio. The company operates in Canada, the United States, the United Kingdom, and Ireland. For more information, visit www.helus.com.
The publication in Nature Medicine underscores the scientific credibility of the data and its potential impact on the treatment landscape for depression. The results suggest that a single-dose regimen could provide rapid and sustained relief, addressing a significant unmet need for patients who do not respond adequately to existing therapies. The full press release is available at https://ibn.fm/etsES. Investors seeking the latest news can visit the company's newsroom at https://ibn.fm/HELP.
